Diagnosis and management of ADA2 deficient polyarteritis nodosa.


Journal

International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930

Informations de publication

Date de publication:
Jan 2019
Historique:
pubmed: 7 4 2018
medline: 29 5 2019
entrez: 7 4 2018
Statut: ppublish

Résumé

Deficiency of ADA2 (DADA2) is a recently described systemic inflammatory vasculopathy caused by mutations in the CERC1 gene that often, but not always, clinically resembles polyarteritis nodosa (PAN). The condition was originally characterized by livedoid rash, systemic inflammation, variable hypogammaglobulinemia, and early-onset stroke. The phenotypic spectrum has expanded to include patients with immunodeficiency syndromes and bone marrow dysfunction, which are not typical features of PAN. Exploration into the pathogenesis and treatment options of DADA2 has added to our understanding of this condition, but more studies are needed. The purpose of this article is to review the various clinical phenotypes of DADA2, and raise awareness among rheumatologists to consider DADA2 when evaluating patients presenting with PAN-like disease.

Identifiants

pubmed: 29624883
doi: 10.1111/1756-185X.13283
doi:

Substances chimiques

Immunosuppressive Agents 0
Intercellular Signaling Peptides and Proteins 0
ADA2 protein, human EC 3.5.4.4
Adenosine Deaminase EC 3.5.4.4

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-77

Informations de copyright

© 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Auteurs

Andrea Human (A)

Division of Rheumatology, Department of Pediatrics, BC Children's Hospital, Vancouver, British Columbia, Canada.

Christian Pagnoux (C)

Vasculitis Clinic, Mount Sinai Hospital, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH